ClinicalTrials.gg
CompletedNCT03383042Updated Apr 22, 2019

Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of JP-1366 Oral Administration in Healthy Male Subjects

A Phase 1 interventional study of Cohort 1 (JP-1366 A mg) and Cohort 2 (JP-1366 B mg) in Anti-Ulcer Agents, sponsored by Jeil Pharmaceutical Co., Ltd.. Completed at 1 site in Korea, Republic of. Open to male participants aged 19 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-04-22.

Sponsored by Jeil Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
115
Allocation
Randomized
Ages
19 Years to 50 Years
Sex
Male
01

Study summary

Clinical trial to investigate the safety, tolerability and pharmacokinetics and pharmacodynamics of JP-1366 oral administration in healthy male subjects

02

Conditions studied

  • Anti-Ulcer Agents

Browse trials for

03

In context

Ulcer

359 studies on the registry are indexed under Ulcer; 60 are open to participants now.

This study's enrollment of 115 is above the median of 65 across 291 interventional studies indexed under Ulcer.

Browse Ulcer studies →

Lead sponsor

Jeil Pharmaceutical Co., Ltd. is the lead sponsor of 38 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adult males aged between 19 and 50 at screening
  • Weight is between 55 and 90 kg and is between 18.0 and 27.0
  • Those who are adequate to be subjects in this study upon judgment of the investigator after physical examination, clinical laboratory test, examination by interview, etc

Exclusion criteria

Exclusion Criteria:

  • Subject has clinical significant liver, kidney, nervous system, respiratory, endocrine, hematology and oncology, cardiovascular, urinary, and mental diseases or past history
  • Subject has gastrointestinal diseases or past history of gastrointestinal diseases (gastrointestinal ulcer, gastritis, gastrospasm, gastroesophageal reflux, Crohn's disease etc.) that may affect safety and pharmacokinetic/pharmacodynamic evaluation of study drug, and those who have past history of gastrointestinal surgery (however, except simple appendectomy and herniotomy)
  • Subject has been Helicobacter pylori positive
  • (SGOT) and ALT (SGPT) > 1.5 times to the in screening including additional examinations prior to randomization
  • Subject has anatomical disability in insertion and maintenance of pH meter catheter
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
115 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Single-ascending cohort 1

    Drug: Cohort 1 (JP-1366 A mg)

  • Experimental
    Cohort 2

    Single-ascending cohort 2

    Drug: Cohort 2 (JP-1366 B mg)

  • Experimental
    Cohort 3

    Single-ascending cohort 3

    Drug: Cohort 3 (JP-1366 C mg)

  • Experimental
    Cohort 4

    Single-ascending cohort 4

    Drug: Cohort 4 (JP-1366 D mg)

  • Experimental
    Cohort 5

    Single-ascending cohort 5

    Drug: Cohort 5 (JP-1366 E mg)

  • Experimental
    Cohort 6

    Multiple-ascending cohort 1

    Drug: Cohort 6 (JP-1366 F mg)

  • Experimental
    Cohort 7

    Multiple-ascending cohort 2

    Drug: Cohort 7 (JP-1366 G mg)

  • Experimental
    Cohort 8

    Multiple-ascending cohort 3

    Drug: Cohort 8 (JP-1366 H mg)

  • Experimental
    Cohort 9

    Multiple-ascending cohort 4

    Drug: Cohort 9 (JP-1366 I mg)

Interventions

  • DrugCohort 1 (JP-1366 A mg)

    Drug: JP-1366 A mg or JP-1366 Placebo or Esomeprazole 40 mg

    Also known as: SAD

  • DrugCohort 2 (JP-1366 B mg)

    Drug: JP-1366 B mg or JP-1366 Placebo or Esomeprazole 40 mg

    Also known as: SAD

  • DrugCohort 3 (JP-1366 C mg)

    Drug: JP-1366 C mg or JP-1366 Placebo or Esomeprazole 40 mg

    Also known as: SAD

  • DrugCohort 4 (JP-1366 D mg)

    Drug: JP-1366 D mg or JP-1366 Placebo or Esomeprazole 40 mg

    Also known as: SAD

  • DrugCohort 5 (JP-1366 E mg)

    Drug: JP-1366 E mg or JP-1366 Placebo or Esomeprazole 40 mg

    Also known as: SAD

  • DrugCohort 6 (JP-1366 F mg)

    Drug: JP-1366 F mg or JP-1366 Placebo or Esomeprazole 40 mg

    Also known as: MAD

  • DrugCohort 7 (JP-1366 G mg)

    Drug: JP-1366 G mg or JP-1366 Placebo or Esomeprazole 40 mg

    Also known as: MAD

  • DrugCohort 8 (JP-1366 H mg)

    Drug: JP-1366 H mg or JP-1366 Placebo or Esomeprazole 40 mg

    Also known as: MAD

  • DrugCohort 9 (JP-1366 I mg)

    Drug: JP-1366 I mg or JP-1366 Placebo or Esomeprazole 40 mg

    Also known as: MAD

06

What researchers measure

Primary outcomes

  1. Cmax

    SAD endpoint

    Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hours post-dose

  2. AUClast

    SAD endpoint

    Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hours post-dose

  3. AUCinf

    SAD endpoint

    Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hours post-dose

  4. tmax

    SAD endpoint

    Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hours post-dose

  5. t1/2

    SAD endpoint

    Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hours post-dose

  6. Cmax,ss

    MAD endpoint

    Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24h post-dose, Day 3-6, pre-dose, Day 7 pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hour post-dose

  7. Cmin,ss

    MAD endpoint

    Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24h post-dose, Day 3-6, pre-dose, Day 7 pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hour post-dose

  8. Cav,ss

    MAD endpoint

    Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24h post-dose, Day 3-6, pre-dose, Day 7 pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hour post-dose

  9. AUCτ

    MAD endpoint

    Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24h post-dose, Day 3-6, pre-dose, Day 7 pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hour post-dose

  10. tmax,ss

    MAD endpoint

    Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24h post-dose, Day 3-6, pre-dose, Day 7 pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hour post-dose

  11. t1/2

    MAD endpoint

    Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24h post-dose, Day 3-6, pre-dose, Day 7 pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hour post-dose

  12. Percentage of total time that the intragastric pH was above 4

    SAD

    Time frame: 0-24 hours(Day -1), 0-24 hours(Day 1)

  13. Percentage of total time that the intragastric pH was above 4

    MAD

    Time frame: 0-24 hours (Day -1), 0-24 hours (Day 1), 0-24 hours (Day 7)

  14. Serum gastrin concentration

    SAD

    Time frame: Pre-dose, 2, 4, 6, 8, 12h post-dose, Day 1 pre-dose, 2, 4, 6, 8, 12, 24, 48h post-dose

  15. Serum gastrin concentration

    MAD

    Time frame: Pre-dose, 2, 4, 6, 8, 12h post-dose, Day 1 pre-dose, 2, 4, 6, 8, 12, 24h post-dose, Day 4 pre-dose, Day 6 pre-dose, Day 7 pre-dose, 2, 4, 6, 8, 12, 24, 48h post-dose

07

Study locations

1 site
  • Seoul National University Hospital(SNUH)
    Seoul, Jongno-Gu 110-744, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2017 to primary completion in Nov 2018, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2017
First posted
Dec 26, 2017
StartActual
Dec 22, 2017
Primary completionActual
Nov 23, 2018
CompletionActual
Apr 5, 2019
Last update
Apr 22, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03383042
Responsible party
Sponsor
First posted
Dec 26, 2017
Start date
Dec 22, 2017
Primary completion
Nov 23, 2018
Completion
Apr 5, 2019
Last update
Apr 22, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion